Key Insights

Highlights

Success Rate

87% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

9.1%

2 terminated out of 22 trials

Success Rate

86.7%

+0.2% vs benchmark

Late-Stage Pipeline

23%

5 trials in Phase 3/4

Results Transparency

38%

5 of 13 completed with results

Key Signals

5 with results87% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (5)
P 1 (2)
P 2 (4)
P 3 (4)
P 4 (1)

Trial Status

Completed13
Recruiting3
Terminated2
Active Not Recruiting2
Unknown1
Withdrawn1

Trial Success Rate

86.7%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (22)

Showing 20 of 20 trials
NCT05250908Not ApplicableActive Not Recruiting

INTIBIA Pivotal Study

NCT03245242Active Not Recruiting

Pediatric Urology Recovery After Surgery Endeavor (PURSUE)

NCT05643963Not ApplicableCompleted

The COOKER-BLADDER Trial

NCT06237920Phase 2Recruiting

Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

NCT04442724Not ApplicableRecruiting

Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy

NCT03081858Phase 1Completed

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

NCT01638000Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.

NCT01340027Phase 2Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder

NCT01908829Phase 3CompletedPrimary

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

NCT02320773Completed

A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice

NCT02386072Completed

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

NCT05153694Recruiting

Infectious Complications After Cystectomy: A Prospective Observational Study

NCT04161716Not ApplicableCompleted

Study Evaluating the Ability of a NIRS Module to Detect a Urodynamic Variation in Humans (DETTECH)

NCT01060254Phase 2Terminated

A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

NCT04922047Phase 1Unknown

Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)

NCT04914442CompletedPrimary

Eosinophilic Cystitis Mimicking Urothelial Neoplasia

NCT03845725Completed

Falls and Balance of Patients With Parkinson's Disease With Urinary Disturbance

NCT02307487Phase 2Completed

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

NCT02891460Not ApplicableCompleted

Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients

NCT01930799Phase 4Completed

Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns

Scroll to load more

Research Network

Activity Timeline